News & Insights https://wound.help en Wed, 25 Feb 2026 11:49:08 +0300 “Laser in Wound Care”? You Probably Think of LLLT. We Don’t. https://wound.help/blog/ujx7pjf041-laser-in-wound-care-you-probably-think-o https://wound.help/blog/ujx7pjf041-laser-in-wound-care-you-probably-think-o?amp=true Wed, 18 Feb 2026 16:21:00 +0300 When someone mentions “laser therapy for wounds,” most clinicians immediately think of low-level laser therapy (LLLT). Photobiomodulation. Low energy. Gentle light. That is not what we are talking about.

“Laser in Wound Care”? You Probably Think of LLLT. We Don’t.

When vascular or diabetic foot surgeons hear “laser therapy for wounds,” most immediately think of low-level photobiomodulation. Gentle light. Adjunct therapy. That is not what we are discussing.

The issue is not simply "cellular activation". Neuroischemic ulcers are not superficial inflammatory lesions. They are hypoxic, colonised, fibrotic environments with impaired microcirculation and structurally altered extracellular matrix.

In daily practice, debridement is performed with a scalpel, curette, or hydrosurgical system. It is effective, but highly operator-dependent. In ischemic tissue, it is difficult to control how much marginally viable tissue is sacrificed. The clinical challenge is clear: remove necrotic zones and biofilm while preserving every millimetre of viable microvascular bed.

A short-pulse Er: YAG laser enables high-precision microablation with minimal thermal diffusion. Tissue interaction is dominated by cavitation rather than heat spread. This enables controlled removal of pathological surface tissue without extending injury into deeper ischemic layers.

But a structural reset alone is not enough.

After precise micro-ablation, tissue still needs to re-enter an active regenerative state. This is where RecoSMA becomes relevant.

RecoSMA is a spatially modulated Er: YAG application that creates thousands of controlled microinteractions across the wound surface. The effect is non-thermal and acoustically mediated. Instead of coagulation, it induces deep micro-stimulation within the tissue, supporting neovascularisation, fibroblast activation, organised granulation, and the transition from stalled chronic inflammation to regenerative repair.

In ischemic diabetic foot ulcers, this dual approach — precise non-thermal sanitation followed by regenerative activation — addresses both sides of the problem: the removal of the pathological substrate and the re-initiation of healing biology.

We expect this combination of high-precision micro-ablation and non-thermal regenerative stimulation to redefine how laser technology is integrated into advanced wound care. Not as adjunctive phototherapy, but as an active structural and biological intervention — potentially setting a new standard for regenerative management of complex ischemic wou

Clinical Case

A 48-year-old female patient presented with a right plantar hindfoot ulcer of three weeks’ duration and an initial wound surface area of 42 cm². The patient was treated using a two-step Er:YAG laser protocol combined with RecoSMA technology, as described by Chilgar and Andurkar in the Journal of Wound Care (2023) .

At each weekly outpatient session, the wound was cleansed with saline and measured prior to treatment. Step one consisted of short-pulse, high-power Er:YAG laser ablation (2940 nm) to precisely debride necrotic tissue and disrupt biofilm. Ablation was continued until capillary bleeding indicated viable tissue had been reached, effectively transitioning the wound into an active healing phase without the need for surgical sharp debridement or anaesthesia.

Step two involved biostimulation using spatially modulated RecoSMA technology. Laser energy was delivered in a microbeam pattern to the wound bed, edges, and surrounding periwound tissue. This created controlled micro-mechanical effects in deeper layers, reactivating the inflammatory cascade and promoting neovascularisation, collagen synthesis, extracellular matrix remodelling, and granulation tissue formation.

Standard wound care was maintained throughout, including alternate-day dressings, topical antiseptics, offloading to reduce plantar pressure, and systemic therapy when indicated. The patient underwent six laser sessions and achieved complete wound closure within seven weeks. Follow-up at 62 months demonstrated sustained healing without recurrence, supporting the effectiveness of the Er:YAG and RecoSMA two-step approach for diabetic plantar ulcers.

Source: Chilgar RM, Andurkar SP. Spatially modulated erbium YAG laser as a treatment for diabetic ulcer. Journal of Wound Care. 2023;32(Silk Road Supplement, October):S21–S29 .
]]> Er:YAG + RecoSMA® Demonstrates Superior Outcomes vs Sharp Debridement in Randomised Clinical Trial https://wound.help/blog/b657oun771-eryag-recosma-demonstrates-superior-outc https://wound.help/blog/b657oun771-eryag-recosma-demonstrates-superior-outc?amp=true Mon, 12 May 2025 15:21:00 +0300 Simon Einstein We are proud to announce the publication of a prospective randomised controlled trial evaluating high-intensity Er:YAG laser therapy with RecoSMA® technology versus conventional sharp debridement for the treatment of chronic lower-extremity ulcers.

Er:YAG + RecoSMA® Demonstrates Superior Outcomes vs Sharp Debridement in Randomised Clinical Trial

Published in the International Wound Journal

We are proud to announce the publication of a prospective randomised controlled trial evaluating high-intensity Er:YAG laser therapy with RecoSMA® technology versus conventional sharp debridement for the treatment of chronic lower-extremity ulcers.

The study, published in the International Wound Journal, included 144 patients with diabetic foot ulcers, venous leg ulcers, and arterial ulcers.

Study Overview

The trial compared two approaches:
  • Treatment group (n=71): High-intensity Er:YAG laser ablation followed by RecoSMA® regenerative mode
  • Control group (n=73): Conventional sharp surgical debridement
Baseline wound characteristics, duration, aetiology, and comorbidities were comparable between groups.
The primary endpoints included:
  • Time to clean the wound bed
  • Time to granulation
  • Marginal and complete epithelialisation
  • Percentage wound area reduction
  • Bacterial clearance
  • Cytological wound progression

Key Clinical Findings

1️⃣ Significantly Higher Wound Closure Rate

After 30 days:

  • 56.3% of wounds in the laser group achieved complete epithelialisation
  • Compared to 26% in the control group
  • (p < 0.001)

This represents more than a twofold increase in full wound closure.

2️⃣ Faster Wound Bed Preparation

Laser-treated wounds demonstrated:

  • Earlier detritus clearance
  • Faster granulation tissue formation
  • Earlier marginal epithelialisation

3️⃣ Greater Reduction in Wound Area

At day 30:

  • 79% average percentage wound area reduction (PWAR) in the laser group
  • Compared to 58% in the control group

Among diabetic foot ulcers, the average PWAR reached 84%.

4️⃣ Enhanced Bacterial Clearance

By day 15:

  • 67.6% of laser-treated wounds showed no bacterial growth
  • Compared to 46.5% in the control group
  • (p < 0.001)

This supports the laser’s ability to disrupt biofilms and reduce microbial burden.

5️⃣ Regenerative Cytological Shift

Cytology analysis revealed:

  • Higher proportion of regenerative cells in the laser group
  • Lower persistence of inflammatory cell dominance

At day 30, regenerative cytograms were substantially more prevalent in the treatment group.

6️⃣ High Tolerability

Laser debridement was reported as painless in:

  • 69% of patients in ablation mode
  • 100% of patients in RecoSMA® mode

No adverse events were reported.

Why This Matters

Chronic wounds are frequently stalled by:

  • Biofilm persistence
  • Non-viable tissue
  • Prolonged inflammatory dominance
  • Impaired microcirculation

This study demonstrates that high-intensity Er:YAG laser therapy combined with RecoSMA® technology offers:

  • Precise removal of necrotic tissue
  • Biofilm disruption
  • Stimulation of neovascularisation
  • ECM remodeling
  • Anti-fibrotic biological activation

Without adding secondary thermal damage to fragile tissue.

A Step Forward in Regenerative Wound Management

The findings suggest that Er:YAG laser therapy in ablation + RecoSMA® mode is a clinically effective and safe alternative to conventional sharp debridement for chronic lower limb ulcers. This publication reinforces the growing body of evidence supporting regenerative laser-based wound management strategies.
]]> RecoSMA® Enters Kuwait: First Clinical Implementation at Farwaniya Hospital https://wound.help/blog/ztxce26hr1-recosma-enters-kuwait-first-clinical-imp https://wound.help/blog/ztxce26hr1-recosma-enters-kuwait-first-clinical-imp?amp=true Thu, 18 Sep 2025 15:21:00 +0300 A significant milestone has been reached in Kuwait. RecoSMA® regenerative laser technology has been clinically introduced at Farwaniya Hospital, Diabetic Foot Department

RecoSMA® Enters Kuwait: First Clinical Implementation at Farwaniya Hospital

A significant milestone has been reached in Kuwait.

RecoSMA® regenerative laser technology has been clinically introduced at Farwaniya Hospital, Diabetic Foot Department, under the leadership of Dr. Nasser Alhumaidi — marking the first application of this regenerative method in the country.

During two intensive clinical training days, the hospital team initiated a structured clinical program for the treatment of diabetic foot ulcers. This is not merely the installation of new equipment — it represents the beginning of a new therapeutic approach in Kuwaiti wound care.

RecoSMA® is a patented, non-thermal laser technology delivering ultra-short pulses precisely tuned to interact with tissue water. Instead of causing coagulative heat damage, it generates controlled micro-acoustic effects that:

  • Support angiogenesis
  • Stimulate extracellular matrix (ECM) remodeling
  • Promote anti-fibrotic biological responses
  • Activate regenerative pathways critical for chronic wound healing

These mechanisms are particularly relevant in ischemic and diabetic wounds, where conventional treatments often reach their limits.

We extend our sincere appreciation to Dr. Nasser Alhumaidi and his clinical team for their commitment to innovation and clinical advancement. Special thanks to our international trainer, Dr. Katarína Szabómihályová, for leading the hands-on sessions, and to Mr. Ghaith Saltaji together with Advanced Technology Company — LINLINE’s distributor in Kuwait — for their strategic support and dedication in bringing this project to life.

At LINLINE Medical Systems SIA, we believe progress in wound care requires more than incremental improvement. It requires a shift in therapeutic logic — from destructive intervention toward precise, regeneration-driven strategies.

Kuwait has now taken that step.
]]> Spatially Modulated Er:YAG Laser for Diabetic Ulcers Published in Journal of Wound Care https://wound.help/blog/rvsd6xj5s1-spatially-modulated-eryag-laser-for-diab https://wound.help/blog/rvsd6xj5s1-spatially-modulated-eryag-laser-for-diab?amp=true Wed, 01 Nov 2023 18:07:00 +0300 A clinical study evaluating the spatially modulated Er:YAG laser combined with RecoSMA® technology for the treatment of diabetic ulcers was published in the Journal of Wound Care

Spatially Modulated Er:YAG Laser for Diabetic Ulcers Published in Journal of Wound Care

Published in Journal of Wound Care | October 2023

A clinical study evaluating the spatially modulated Er:YAG laser combined with RecoSMA® technology for the treatment of diabetic ulcers was published in the October 2023 issue of the Journal of Wound Care (Vol 32, No 10, Silk Road Supplement).

The study, led by Dr. Ram M. Chilgar (India), assessed a two-step regenerative laser protocol in 59 patients with hard-to-heal diabetic ulcers.

Study Overview

Patients received weekly treatment consisting of:

  1. High-power Er:YAG laser ablation to remove necrotic tissue and biofilm
  2. RecoSMA®-mediated spatial modulation to stimulate deep tissue regeneration

The primary endpoint was complete wound closure.

Key Clinical Findings

  • 100% wound closure achieved in all 59 patients
  • Mean number of sessions required: 4.41
  • Average initial wound area: 25 cm²
  • No recurrence observed during long-term follow-up (average 22.95 months)

Mechanistic Insight

The authors describe how Er:YAG laser ablation rapidly vaporises devitalised tissue while avoiding collateral thermal injury. RecoSMA® technology spatially modulates the laser beam into microbeams that create controlled mechanical resonance waves in deeper tissue layers.

This process:

  • Retriggers the inflammatory phase
  • Stimulates fibroblast proliferation
  • Promotes collagen and extracellular matrix formation
  • Enhances neoangiogenesis

Selected Quotes from the Publication

“Er-YAG lasers achieved wound closure in all 59 hard-to-heal diabetic ulcers with a mean of 4.41 treatments.”

“Debridement and biostimulation of the patients’ own inflammatory mechanism resulted in complete healing.”

“The treatment was convenient for the patients as it could be performed on an outpatient basis.”

“RecoSMA technology provided a convenient, cost-effective and efficient solution to diabetic ulcer healing.”

Clinical Implications

Diabetic foot ulcers remain a leading cause of lower limb amputation worldwide. The study suggests that Er:YAG laser combined with RecoSMA® may offer:

  • Effective outpatient treatment
  • Reduced need for surgical reconstruction
  • Accelerated healing through regenerative stimulation
  • A non-thermal, biologically controlled intervention

This publication contributes to the expanding clinical evidence supporting regenerative laser strategies in chronic wound management.
]]> Randomized Clinical Trial on Er:YAG + RecoSMA® for Neuroischemic Diabetic Foot Ulcers Launched at Complutense University of Madrid https://wound.help/blog/612miy69s1-randomized-clinical-trial-on-eryag-recos https://wound.help/blog/612miy69s1-randomized-clinical-trial-on-eryag-recos?amp=true Sun, 30 Nov 2025 18:20:00 +0300 LINLINE Medical Systems SIA announces the initiation of a prospective randomised clinical study evaluating the effect of Er:YAG laser therapy combined with RecoSMA® technology in the treatment of neuroischemic diabetic foot ulcers.

Randomized Clinical Trial on Er:YAG + RecoSMA® for Neuroischemic Diabetic Foot Ulcers Launched at Complutense University of Madrid

The study, titled:

“Effect of Erbium Laser on the Evolution of Neuroischemic Ulcers in Diabetic Feet,”

is being conducted at the Diabetic Foot Unit of the University Podiatry Clinic, Faculty of Medicine, Complutense University of Madrid.

Principal Investigator:

Prof. Dr. José Luis Lázaro Martínez

Co-Investigators:

Prof. Dr. Aroa Tardáguila García
Ms. Teeana Alexandra Luna Sánchez 28. MADRID RCT

Clinical Background

Neuroischemic diabetic foot ulcers represent one of the most complex and difficult-to-treat complications of diabetes mellitus. These lesions combine:

  • Peripheral neuropathy
  • Peripheral arterial disease
  • Reduced tissue perfusion
  • Chronic inflammation

Despite standardised treatment protocols—including debridement, dressings, offloading, and metabolic control—a significant proportion of ulcers remain hard-to-heal, increasing the risk of infection, recurrence, and amputation 28. MADRID RCT

Given the high lifetime incidence of diabetic foot ulcers and recurrence rates approaching 40% within one year, there is a clear need for adjunctive regenerative therapies.

Study Design

This investigation is a prospective, randomised, quasi-experimental study with a 1:1 allocation ratio:

  • Intervention group: Er:YAG laser with RecoSMA® technology in addition to conventional care
  • Control group: Conventional treatment alone

Participants will be followed for six weeks with structured weekly assessments.


The primary objective is to evaluate whether Er:YAG laser with RecoSMA® technology enhances tissue regeneration and accelerates healing in neuroischemic ulcers compared to standard therapy.

Secondary objectives include:

  • Analysis of granulation tissue progression
  • Evaluation of epithelialization rate
  • Assessment of microcirculatory changes

Objective Perfusion Assessment

A distinctive feature of this trial is the integration of hyperspectral imaging for quantitative perfusion analysis.

The following parameters will be measured:

  • Tissue oxygen saturation (StO₂%)
  • Total haemoglobin (THb)
  • Perfusion index
  • Oxygenation gradient (ΔStO₂)

This approach enables objective evaluation of microvascular and oxygenation changes during treatment.

Biological Rationale

The protocol outlines a dual mechanism of action:

  1. Er:YAG Laser Ablation
  2. Precise removal of devitalized tissue with minimal thermal impact.
  3. RecoSMA® Spatial Modulation
  4. Division of the laser beam into microbeams generating controlled acoustic effects in superficial tissue layers.
  5. These effects stimulate:

  • Microcirculation
  • Fibroblast activation
  • Collagen synthesis
  • Extracellular matrix remodeling
  • Neovascularization

The study hypothesis states that Er:YAG + RecoSMA® promotes tissue regeneration, enhances granulation tissue formation, accelerates epithelialization, and reduces healing time compared to conventional treatment 28. MADRID RCT

Sample Size and Statistical Framework

The planned sample size is:

  • 36 patients per group (72 total)

The study is powered to detect a clinically meaningful ≥20% difference in ulcer area reduction between groups, with statistical analysis performed using IBM SPSS software

Advancing Evidence in Regenerative Wound Care

This randomised clinical investigation represents an important step toward generating high-level evidence for:

  • Laser-assisted regenerative wound management
  • Objective perfusion-based outcome measurement
  • Protocol-driven application of Er:YAG + RecoSMA® technology

LINLINE Medical Systems SIA is proud to support this academic collaboration and looks forward to the publication of the clinical results upon completion of the study.
]]> The Other Side of Lasers: From Heat to Regeneration https://wound.help/blog/78z98bng91-the-other-side-of-lasers-from-heat-to-re https://wound.help/blog/78z98bng91-the-other-side-of-lasers-from-heat-to-re?amp=true Wed, 25 Feb 2026 11:28:00 +0300 Most people think lasers work by heating tissue. Cut. Burn. Coagulate. But what if a laser could stimulate regeneration — without heating the skin at all?

The Other Side of Lasers: From Heat to Regeneration

For decades, lasers in medicine have been primarily associated with heat. Surgical cutting. Coagulation.
Tissue vaporisation. And rightly so — high-energy laser systems have provided precision that conventional instruments cannot match.

But limiting laser technology to its thermal effect overlooks its most intriguing potential.
Laser energy is not defined by heat. It is defined by its interactions with tissue.

Beyond Photothermal Effects

Traditional laser-tissue interaction models focus on photothermal mechanisms: energy absorption leads to a temperature increase, which results in coagulation or ablation.

However, when parameters such as pulse duration, energy density, and spatial modulation are precisely controlled, laser radiation can produce non-thermal biological effects.

RecoSMA technology represents such an approach.

How RecoSMA Works

Instead of delivering a single continuous beam, the system distributes approximately 10,000 microbeams per square centimetre.

Each microbeam is thinner than a human hair.

Each pulse carries high energy but is delivered over an ultra-short time window — shorter than the tissue's thermal relaxation time.

As a result:

  • Surface temperature remains at physiological levels (~36.6°C)
  • No bulk heating occurs
  • No visible burns or coagulative necrosis are observed

At the dermal–epidermal junction, each microbeam produces instantaneous micro-evaporation of microscopic tissue volumes.

Individually, these events are extremely small.

Collectively, they generate something far more significant.

Mechanical-Acoustic Resonance

The thousands of micro-events generate mechanical-acoustic waves that propagate into deeper layers of tissue — up to 6 mm.

These waves do not rely on heat.

Instead, they create controlled micro-disruption of selected cellular structures, including partial membrane and nuclear alterations at a microscopic scale.

Importantly:

  • No widespread necrosis occurs
  • Surrounding tissue remains viable
  • No thermal fibrosis is induced

The intervention is minimal.

The biological response is not.

Triggering Regeneration

The controlled micro-disruption activates:

  • Inflammatory phase re-initiation
  • Fibroblast activation
  • Neoangiogenesis
  • Collagen remodeling
  • Epithelial migration

In essence, the tissue behaves as if it has received a precisely dosed regenerative stimulus.

Rather than destroying tissue to remove pathology, the approach stimulates intrinsic repair mechanisms.

Why This Matters

Chronic wounds, fibrotic tissue, and certain degenerative conditions share one common feature: stalled healing.

In such cases, the problem is not insufficient temperature.

It is insufficient biological activation.

Mechanical-acoustic stimulation enables reactivation of physiological repair cascades without large-scale destruction.

This represents a shift:

From thermal intervention

To regenerative modulation

Rethinking Laser Technology

The common perception of lasers as “cutting tools” reflects only one aspect of their capabilities.

Modern laser systems allow:

  • Selective microablation
  • Spatial energy distribution
  • Non-thermal stimulation
  • Controlled cellular microtrauma

The key variable is not power.

It is precision.

The future of laser medicine may not lie in stronger heat.

It may lie in smarter energy delivery.
]]>